BGT-002 / Burgeon Therap - LARVOL DELTA

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects. (PubMed, Drug Des Devel Ther) - P1 | "BGT-002 demonstrated favorable safety, tolerability, and lipid-lowering effects, supporting its potential for further clinical development. ChiCTR2200057793(https://www.chictr.org.cn/showproj.html?proj=160210); ChiCTR2300067474(https://www.chictr.org.cn/showproj.html?proj=182183); ChiCTR2300067472(https://www.chictr.org.cn/showproj.html?proj=184079)."

Clinical • Journal • P1 data • PK/PD data • Dyslipidemia

A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis (clinicaltrials.gov) - P1/2 | N=48 | Completed | Sponsor: Burgeon Therapeutics Co., Ltd.

New P1/2 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

A randomized, placebo-controlled phase Ib/IIa trial to evaluate the safety, tolerability, and efficacy of BGT-002, an adenosine triphosphate citrate lyase inhibitor in patients with NAFLD: interim analysis (EASL-ILC 2024) - "The findings from interim analysis of this study, it was observed that a significant reduction in LFC , lipids and GGT level of NAFLD patients enrolled after 28-days treatment. BGT- 002 is safe and well-tolerated. And it might be a promising for NAFLD."

Clinical • P1/2 data • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease